Sarepta Therapeutics (SRPT) PT Trimmed to $96 at Baird; BioMarin Deal Not a Huge Event But Removes IP Overhang
Tweet Send to a Friend
Baird analyst Brian Skorney lowered his price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $102.00) on higher COGS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
